Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

Tzung-Huei Lai, PhD, Alma Zecevic, Brett Ewald, PhD, Liu Chaomei, Lara Rizzotto, PhD, Melanie Sulda, Dimitrios Papaioannou, MD, Ramiro Garzon, MD, William Plunkett, PhD, Deepa Sampath, PhD

Blood (2015) 126 (23): 3639.

https://doi.org/10.1182/blood.V126.23.3639.3639

Published: 2015

Journal Articles

Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine

Deepa Sampath, PhD, Alma Zecevic, PhD, Brett Ewald, PhD, Melanie Hayes, PhD, Chaomei Liu, BSc, Guido Marcucci, MD, William Plunkett, PhD

Blood (2013) 122 (21): 822.

https://doi.org/10.1182/blood.V122.21.822.822

Published: 2013

Journal Articles

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Michelle Fanale, MD, William I Bensinger, MD, John C. Byrd, MD, Brett Ewald, PhD, Daniel Carreon, PhD, Johan Baeck, MD, Arnold S. Freedman, MD

Blood (2011) 118 (21): 3702.

https://doi.org/10.1182/blood.V118.21.3702.3702

Published: 2011

Journal Articles

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Arnold S. Freedman, MD, John Kuruvilla, MD, Sarit E. Assouline, MD, Andreas Engert, MD, DaeSeog Heo, MD, Philippe Solal-Celigny, MD, Paolo Corradini, MD, Gregor Verhoef, MD, PhD, Michelle A. Fanale, MD, Jennifer Bendiske, PhD, Brett Ewald, PhD, Jyotirmoy Dey, PhD, Johan Baeck, MD, Anas Younes, MD

Blood (2010) 116 (21): 284.

https://doi.org/10.1182/blood.V116.21.284.284

Published: 2010

Journal Articles

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation

Deepa Sampath, George A. Calin, Vinay K. Puduvalli, Gopal Gopisetty, Cristian Taccioli, Chang-Gong Liu, Brett Ewald, Chaomei Liu, Michael J. Keating, William Plunkett

Blood (2009) 113 (16): 3744–3753.

https://doi.org/10.1182/blood-2008-09-178707

Published: 2009

Includes: Supplemental data

NARROW

HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation

Email alerts

ASH Publications

American Society of Hematology

HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only